Stallion India Fluorochemicals Releases Q4 & FY26 Earnings Call Transcript
Stallion India Fluorochemicals reported FY25-26 revenue of ₹434.12 crore (up 14.4% YoY), with PAT at ₹43.84 crore (up 35.61%). The company is on track for its R-32 plant in Bhilwara by October 2026 and expanding specialty gas facilities. Management targets 30-35% revenue CAGR over three years.
The announcement provides an update on financial performance and significant expansion projects, which are material to investors. However, it does not involve immediate new orders, mergers, or acquisitions that would have a high immediate impact.
The company reported strong year-on-year financial growth in revenue, EBITDA, and PAT. Key expansion projects are progressing as planned, and management expressed confidence in future growth targets.
Stallion India Fluorochemicals Limited has released the transcript of its Investor Conference call held on May 18, 2026, discussing the company's financial performance for the quarter and financial year ended March 31, 2026. During FY25-26, the company reported a total revenue of ₹434.12 crore, an increase of 14.4% year-on-year. EBITDA grew by 23.34% to ₹61.35 crore, and PAT increased by 35.61% to ₹43.84 crore.
The company received environmental clearance for its proposed 10,000 metric ton R-32 manufacturing facility at Bhilwara, Rajasthan, expected to commence production by October 2026. This facility aims to enhance supply chain security and improve operating margins.
Furthermore, Stallion India Fluorochemicals is expanding its specialty and high-purity gas capabilities with upcoming facilities in Mumbattu, Andhra Pradesh, and scaling up liquid helium semiconductor gas infrastructure at Khalapur. The company targets a revenue growth CAGR of 30-35% over the next three years, with projected margin improvements of 3-4%.
During the Q&A session, management addressed investor queries regarding shareholding dilution, revenue growth, expansion project timelines, and the impact of geopolitical factors on commodity prices and supply chains. The company reiterated its commitment to innovation, reliability, sustainability, and long-term stakeholder value creation.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.